Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $89.00 short put and a strike $84.00 long put offers a potential 30.21% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $89.00 by expiration. The full premium credit of $1.16 would be kept by the premium seller. The risk of $3.84 would be incurred if the stock dropped below the $84.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 58.88 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Gilead receives positive opinion from CHMP for Zydelig
Fri, 25 Jul 2014 11:25:17 GMT
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Fri, 25 Jul 2014 11:24:00 GMT
Business Wire – Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig® , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular lymphoma , the most common subtype of indolent non-Hodgkin …
Europe backs new leukaemia drugs from J&J and Gilead
Fri, 25 Jul 2014 11:20:26 GMT
Reuters – Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib. Ibrutinib, marketed at Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukaemia (CLL) in February, while Gilead's idelalisib, which has the brand name Zydelig, was approved in the United States last month.
Why Gilead Sciences, inc. Stock Was Flat Today
Thu, 24 Jul 2014 23:08:17 GMT
Celgene, Alexion Beat Estimates, But Biotechs Fall
Thu, 24 Jul 2014 21:07:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook